Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 7/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | IL1B | P01584 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12041909 | 0.87 | DDB1 (0.53) | CASP3DDB1CRBNALDH1A1IKZF3 | |
| SCHEMBL5617530 | 0.82 | DDB1 (0.57) | DDB1CRBNALDH1A1IKZF3TDP1 | |
| SCHEMBL2919642 | 0.82 | CRBN (0.50) | DDB1CRBNALDH1A1IKZF3CHRM2 | |
| SCHEMBL4103132 | 0.82 | DDB1 (0.50) | DDB1CRBNALDH1A1IKZF3CHRM2 | |
| SCHEMBL4120260 | 0.80 | ALDH1A1 (0.50) | CASP3DDB1CRBNALDH1A1IKZF3 | |
| SCHEMBL4929916 | 0.80 | CRBN (0.48) | DDB1CRBNALDH1A1IKZF3CHRM2 | |
| SCHEMBL2172756 | 0.77 | GAA (0.54) | CASP3DDB1CRBNALDH1A1IKZF3 | |
| SCHEMBL5507404 | 0.77 | CRBN (0.54) | DDB1CRBNALDH1A1IKZF3CHRM2 | |
| SCHEMBL4939061 | 0.76 | ALDH1A1 (0.46) | DDB1CRBNALDH1A1IKZF3CHRM2 | |
| SCHEMBL13529621 | 0.75 | CRBN (0.44) | DDB1CRBNALDH1A1IKZF3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156641-A1 | INHIBITION OF CYCLOOXYGENASE-2 ACTIVITY | CELGENE CORPORATION | 2009-06-18 | — | — | US | disclosed |
| US-20060199819-A1 | Inhibition of cyclooxygenase-2 activity | CELGENE CORPORATION | 2006-09-07 | — | — | US | disclosed |
| US-20040077686-A1 | Inhibition of cyclooxygenase-2 activity | CORNELL RESEARCH FOUNDATION, INC. | 2004-04-22 | — | — | US | disclosed |
| EP-1272189-A4 | INHIBITION OF CYCLOOXYGENASE-2 ACTIVITY | CELGENE CORP (US) | 2004-01-14 | — | — | EP | disclosed |
| EP-1272189-A1 | INHIBITION OF CYCLOOXYGENASE-2 ACTIVITY | CELGENE CORPORATION (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020022627-A1 | Inhibition of cyclooxygenase-2activity | CORNELL RESEARCH FOUNDATION, INC. | 2002-02-21 | — | — | US | disclosed |
| WO-2001074362-A1 | INHIBITION OF CYCLOOXYGENASE-2 ACTIVITY | CELGENE CORPORATION (US) | 2001-10-11 | — | — | WO | disclosed |
| US-5385901-A | Treating patients with 3-phthalimido-2,6-dioxopiperidine for toxic symptoms of septic shock, cachexia and HIV infection by inhibiting excessive production of tumor necrosis factor alpha | THE ROCKEFELLER UNIVERSITY (US) | 1995-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022627-A1 | Inhibition of cyclooxygenase-2activity | PTGS2, PTGES2, PTGS1 | CASP3 2067/4885DDB1 4349/4885CRBN 4224/4885 |
| US-20090156641-A1 | INHIBITION OF CYCLOOXYGENASE-2 ACTIVITY | PTGS2, PTGS1, PTGES2 | CASP3 1876/4885DDB1 3900/4885CRBN 4658/4885 |
| US-20040077686-A1 | Inhibition of cyclooxygenase-2 activity | PTGS2, PTGS1, PTGES2 | CASP3 1876/4885DDB1 3900/4885CRBN 4658/4885 |
| US-20060199819-A1 | Inhibition of cyclooxygenase-2 activity | PTGS2, PTGS1, PTGES2 | CASP3 1876/4885DDB1 3900/4885CRBN 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.